Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. in vivo data
Show results for
Products
Services
Software

Companies

News
Articles

Refine by
Date

  • This Year
  • Older

In Vivo Data Articles & Analysis

19 news found

Navigating the Future of Preclinical Research: Aligning with the FDA’s Roadmap on Animal Testing

Navigating the Future of Preclinical Research: Aligning with the FDA’s Roadmap on Animal Testing

The Food and Drug Administration’s (FDA) recent Roadmap to Reducing Animal Testing in Preclinical Safety Studies marks a pivotal shift toward the adoption of innovative, human-relevant methodologies commonly known as New Approach Methodologies (NAMs). As leaders in preclinical research tools, we welcome this movement towards advanced and validated NAMs solutions already in place. emka ...

BySCIREQ - an emka TECHNOLOGIES Company


Understanding Lung Biomechanics In Asthma By Combining ex vivo with in vivo

Understanding Lung Biomechanics In Asthma By Combining ex vivo with in vivo

Asthma remains a complex and multifactorial disease, with airway hyperresponsiveness to methacholine being a hallmark feature. A recent study by Rojas-Ruiz et al (2025) utilizes SCIREQ’s innovative physioLens (ex vivo) and flexiVent (in vivo) platforms to shed light on the interplay between lung tissue compliance and methacholine response, offering new insights into the mechanisms ...

BySCIREQ - an emka TECHNOLOGIES Company


Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

(NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with immune checkpoint inhibitor (ICI) ...

ByBeyond Air Inc


Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

Today, we showcased the robust process performance of the Cocoon® system as well as first encouraging biomarker patient data of the CAR-T expansion profile with a 7 day-point-of-care vein-to-vein treatment. ...

ByGalapagos NV


PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

(KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology drug candidates, at SITC (Society for Immunotherapy of Cancer) Annual Meeting taking place November 8-12 in Boston. ...

ByPharmAbcine Inc.


Senti Bio Highlights Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells in Three Presentations at ASGCT Annual Meeting

Senti Bio Highlights Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells in Three Presentations at ASGCT Annual Meeting

The presentations highlight new data related to the application of gene circuit technology to enhance efficacy and safety of cancer-killing allogeneic chimeric antigen receptor (CAR) natural killer (NK) cells. ...

BySenti Biosciences


Bit225 Effective Against Established Sars-Cov-2 in Animals

Bit225 Effective Against Established Sars-Cov-2 in Animals

In a significant step forward, new data shows that BIT225 protects from severe disease even when started once there is an established infection. ...

ByBiotron Limited


Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness

Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness

Similar to the company’s recently announced pipeline expansion into auditory neurons for the treatment of hearing loss, Lineage has filed for intellectual property protection covering the composition and methods for generating PNCs. Based on recent in vivo data generated using the company’s PNCs, these cells may be capable of forming reconstructed ...

ByLineage Cell Therapeutics, Inc.


Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics

Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics

Both MB097 and MB310 are precision medicines derived by highly accurate clinical microbiome profiling using Microbiotica’s platform which links consortia of bacteria with clinical trial outcome data. Both products have also been validated and mechanistically characterised pre-clinically through in vivo efficacy data and ex ...

ByMicrobiotica Limited


T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T

T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T

In vivo data presented at the SITC annual meeting highlight the potential of T-knife’s lead product candidate TK-8001, a TCR engineered T cell therapy (TCR-T) that is being developed to treat MAGE-A1 positive solid tumors. ...

ByT-Knife GmbH


Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS

Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS

SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with MRCLS) and the disease control rate was 85% As of the data cut-off, afami-cel has shown a favorable benefit:risk ...

ByAdaptimmune LLC


Obsidian Therapeutics to Present In Vivo Anti-TumorEfficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021

Obsidian Therapeutics to Present In Vivo Anti-TumorEfficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC). ...

ByObsidian Therapeutics, Inc.


Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E-Based ADCs

Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E-Based ADCs

Separately, Synaffix was also awarded ‘Runner-Up’ for the Best ADC Platform Technology. New data presented in the winning poster, titled: “GlycoConnect™ ADCs Based on Topoisomerase 1 Inhibitor Exatecan (SYNtecan E™) Show Excellent In Vivo Efficacy and Tolerability Data” demonstrated complete tumor regression ...

BySynaffix BV


Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography

Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography

Results showed classification measured against ex vivo data was more than sufficient for clinical use and was able to determine plaque stability efficiently. ...

ByElucid


Microbiotica`s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

Microbiotica`s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy Data show potent anti-tumour efficacy in vivo and in vitro MB097 is in manufacturing process development for Ph1b study expected to start next year MB097 is the first microbiome precision medicine in immuno-oncology, ...

ByMicrobiotica Limited


Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

This has driven us to design a microbiome therapeutic to improve patient response rate. Through our MELRESIST study data and our platform, we have been able to identify a consistent bacterial signature predictive of drug response in advanced melanoma and NSCLC. “The Live Bacterial Therapeutic, MB097, arising from this signature, aims to tap into this predictive signature ...

ByMicrobiotica Limited


Studies suggest Elucid’s AI software helps to objectively quantify key drivers of stroke and heart attack from computed tomography angiography (CTA)

Studies suggest Elucid’s AI software helps to objectively quantify key drivers of stroke and heart attack from computed tomography angiography (CTA)

Results showed classification measured against ex vivo data was more than sufficient for clinical use and was able to determine plaque stability efficiently. ...

ByElucid


BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

It combines deep learning, automation, advanced biomedical knowledge and massive amounts of in vitro and in vivo data to accurately identify targetable molecular mechanisms and guide the discovery and development of oligonucleotide therapies. ...

ByDeep Genomics


Amanda Kay Appointed Chief Business Officer of Deep Genomics, Tasked with Overseeing Expansion of Partnership Strategy

Amanda Kay Appointed Chief Business Officer of Deep Genomics, Tasked with Overseeing Expansion of Partnership Strategy

The AI Workbench combines deep learning, automation, advanced biomedical knowledge and massive amounts of in vitro and in vivo data to accurately identify targetable molecular mechanisms and guide the discovery and development of oligonucleotide therapies. ...

ByDeep Genomics

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT